INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Aga...
July 15 2014 - 8:32AM
Business Wire
Glancy Binkow & Goldberg LLP reminds investors of Vertex
Pharmaceuticals Incorporated (“Vertex” or the “Company”)
(NASDAQ:VRTX) that all purchasers of Vertex common stock between
May 7, 2012 and May 29, 2012, inclusive (the “Class Period”) have
until July 28, 2014, to file a motion to be appointed as lead
plaintiff in the shareholder lawsuit.
Vertex is engaged in discovering, developing, manufacturing and
commercializing small molecule drugs for patients with serious
diseases. The Company markets Kalydeco in the United States and
European Union as a treatment for patients aged six years and older
with a rare form of cystic fibrosis. The Complaint alleges that the
Company issued false and misleading public statements concerning
Vertex’s products VX-809 and Kalydeco.
On May 29, 2012, the Company issued a correction of the interim
analysis of the Phase 2 Combination Study of VX-809 and Kalydeco,
stating that the correction was due to a “misinterpretation”
between Vertex and a third-party statistical analysis vendor over
the study data. Following this news, the Company’s stock price
plummeted from its previous closing price of $64.85 on May 25,
2012, to close at $57.80 per share on May 29, 2012.
If you are a member of the Class described above, you may move
the Court no later than July 28, 2014, to serve as lead plaintiff;
however, you must meet certain legal requirements. To be a member
of the Class, you need not take any action at this time; you may
retain counsel of your choice or take no action and remain an
absent member of the Class. If you wish to learn more about this
action or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact
Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, at
(646) 539-8980, by e-mail to shareholders@glancylaw.com, or visit
our website at http://www.glancylaw.com. If you inquire by email,
please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CALesley Portnoy,
646-539-8980shareholders@glancylaw.comwww.glancylaw.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024